Bogart Wealth LLC Has $6.49 Million Stock Position in Zoetis Inc. $ZTS

Key Points

• Bogart Wealth LLC increased its stake in Zoetis Inc. by 14.5% during Q2, now holding 41,589 shares valued at approximately $6.49 million.
• Zoetis reported a Q2 earnings per share (EPS) of $1.76, exceeding the consensus estimate of $1.62, with revenues of $2.46 billion.
• The company declared a quarterly dividend of $0.50 per share, with a dividend yield of 1.4%, payable on December 2nd to stockholders of record as of October 31st.

Bogart Wealth LLC grew its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 14.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 41,589 shares of the company's stock after purchasing an additional 5,260 shares during the quarter. Bogart Wealth LLC's holdings in Zoetis were worth $6,486,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Nova Wealth Management Inc. bought a new stake in shares of Zoetis in the 1st quarter valued at about $25,000. 1248 Management LLC bought a new stake in Zoetis in the first quarter valued at approximately $27,000. Saudi Central Bank bought a new stake in Zoetis in the first quarter valued at approximately $29,000. REAP Financial Group LLC increased its stake in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company's stock valued at $31,000 after purchasing an additional 131 shares in the last quarter. Finally, Cornerstone Planning Group LLC increased its stake in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after purchasing an additional 88 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $144.15 on Monday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The company has a market capitalization of $63.88 billion, a P/E ratio of 24.81, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The company's 50 day moving average price is $148.73 and its two-hundred day moving average price is $153.65. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $193.49.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping the consensus estimate of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's quarterly revenue was up 4.2% on a year-over-year basis. During the same period last year, the company posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.4%. Zoetis's dividend payout ratio (DPR) is 34.42%.

Analysts Set New Price Targets

ZTS has been the subject of several recent analyst reports. Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Zoetis in a research note on Wednesday, October 8th. Finally, Argus restated a "buy" rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $196.71.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.